2024
Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchMeSH KeywordsCardiomyopathiesFemaleFurosemideHeart FailureHumansMalePatient DischargeStroke VolumeTorsemideTreatment OutcomeVentricular Function, LeftConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbiditiesSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisFactors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice
Faridi K, Zhu Z, Shah N, Crandall I, McNamara R, Flueckiger P, Bachand K, Lombo B, Hur D, Agarwal V, Reinhardt S, Velazquez E, Sugeng L. Factors associated with reporting left ventricular ejection fraction with 3D echocardiography in real‐world practice. Echocardiography 2024, 41: e15774. PMID: 38329886, DOI: 10.1111/echo.15774.Peer-Reviewed Original ResearchMeSH KeywordsEchocardiography, Three-DimensionalFemaleHumansMaleStroke VolumeVentricular Function, LeftConceptsTransthoracic echocardiogramVentricular ejection fractionOutpatient transthoracic echocardiogramsReal-world practiceEjection fractionLeft ventricular ejection fractionAssess left ventricular ejection fractionInpatient transthoracic echocardiogramsMultivariate logistic regressionLVEFHospitalized patientsMedical CenterSonographersClinical settingLogistic regressionUltrasound machineChemotherapyContrast enhancement agentsPortable studiesNegative association
2023
Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images
Sangha V, Nargesi A, Dhingra L, Khunte A, Mortazavi B, Ribeiro A, Banina E, Adeola O, Garg N, Brandt C, Miller E, Ribeiro A, Velazquez E, Giatti L, Barreto S, Foppa M, Yuan N, Ouyang D, Krumholz H, Khera R. Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images. Circulation 2023, 148: 765-777. PMID: 37489538, PMCID: PMC10982757, DOI: 10.1161/circulationaha.122.062646.Peer-Reviewed Original ResearchMeSH KeywordsAdultElectrocardiographyHumansLongitudinal StudiesProspective StudiesVentricular Dysfunction, LeftVentricular Function, LeftConceptsLV systolic dysfunctionYale-New Haven HospitalVentricular systolic dysfunctionSystolic dysfunctionLV ejection fractionBrazilian Longitudinal StudyNew Haven HospitalEjection fractionCardiology clinicRegional hospitalLeft ventricular systolic dysfunctionCedars-Sinai Medical CenterAdult Health (ELSA-Brasil) cohortSacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan M, Mentz R, Claggett B, Miao Z, Kulac I, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Lefkowitz M, McMurray J, Braunwald E, Solomon S. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal 2023, 44: 2982-2993. PMID: 37210743, PMCID: PMC10424880, DOI: 10.1093/eurheartj/ehad344.Peer-Reviewed Original ResearchMeSH KeywordsAminobutyratesAngiotensin Receptor AntagonistsDrug CombinationsHeart FailureHumansStroke VolumeTetrazolesValsartanVentricular Function, LeftConceptsSacubitril/valsartanRenal composite endpointPARAGON-HFHeart failureEjection fractionPooled analysisHF eventsRenal eventsCardiovascular deathComposite endpointLeft ventricular ejection fractionVentricular ejection fractionActive-controlled trialParticipant-level dataPrimary endpointSecondary endpointsClinical outcomesNatriuretic peptideLike patientsTreatment benefitCare settingsPatientsPrimary analysisLVEFValsartan
2021
Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau J, Panza J, Velazquez E, O'Connor C, Investigators W, Dabrowski R, Djokovic L, Drazner M, Haddad H, Ali I, Keltai M, Naik A, Sopko G, Golba K, Andersson B, Carson P, Kukulski T. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal Of Thoracic And Cardiovascular Surgery 2021, 164: 1890-1899.e4. PMID: 33610365, PMCID: PMC8260609, DOI: 10.1016/j.jtcvs.2020.12.094.Peer-Reviewed Original ResearchMeSH KeywordsCardiomyopathiesCoronary Artery DiseaseHeart FailureHumansMyocardial IschemiaStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsOptimal medical therapyCoronary artery bypassMedical therapyArtery bypassIschemic cardiomyopathyCause mortalityIschemic Heart Failure (STICH) trialVentricular ejection fraction 35Improved long-term survivalEjection fraction 35Angiotensin receptor blockersHeart Failure TrialLower cardiovascular mortalityMultivariable Cox modelOutcomes of patientsVentricular ejection fractionCoronary artery diseaseLong-term outcomesLong-term survivalSurgical revascularizationReceptor blockersCardiovascular mortalityAntiplatelet drugsArtery diseaseEjection fraction
2019
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy
Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. New England Journal Of Medicine 2019, 381: 739-748. PMID: 31433921, PMCID: PMC6814246, DOI: 10.1056/nejmoa1807365.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassEchocardiography, StressFemaleFollow-Up StudiesHeartHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaProportional Hazards ModelsProspective StudiesStroke VolumeTomography, Emission-Computed, Single-PhotonTreatment OutcomeVentricular Function, LeftConceptsLeft ventricular ejection fractionVentricular ejection fractionMedical therapyEjection fractionMyocardial viabilityIschemic cardiomyopathyLeft ventricular systolic functionGoals of revascularizationCoronary artery bypassPrimary end pointVentricular systolic functionCoronary artery diseaseLeft ventricular functionLong-term outcomesLong-term survivalSurgical revascularizationDobutamine echocardiographyMedian durationSystolic functionArtery diseaseVentricular functionViable myocardiumLong-term benefitsLower incidenceCABGGlobal Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus
Alenezi F, Bloomfield GS, Okeke NL, Velagapudi P, Abudaqa L, Ijioma N, Dunning A, Alajmi H, Clement ME, Shah SH, Naggie S, Velazquez EJ. Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. The American Journal Of Cardiology 2019, 124: 966-971. PMID: 31371060, PMCID: PMC6887515, DOI: 10.1016/j.amjcard.2019.06.013.Peer-Reviewed Original ResearchConceptsLV ejection fractionHIV-1 RNA viral loadNormal LV ejection fractionRNA viral loadHuman immunodeficiency virusViral loadImmunodeficiency virusImmune statusGlobal longitudinal strain analysisNadir CD4 cell countPreclinical left ventricular dysfunctionDuke University Medical CenterCD4 cell countPlasma HIV RNALeft ventricular dysfunctionGlobal longitudinal strainCells/Longitudinal strain analysisUniversity Medical CenterCD4 cell count dataAbnormal GLSNadir CD4CD4 countHIV RNAVentricular dysfunction
2018
Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure
Alenezi F, Ambrosy AP, Phelan M, Chiswell K, Abudaqa L, Alajmi H, Kisslo J, Velazquez EJ. Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure. Journal Of The American Society Of Echocardiography 2018, 32: 317-318. PMID: 30552031, DOI: 10.1016/j.echo.2018.10.009.Peer-Reviewed Original ResearchPredictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation
Alenezi F, Fudim M, Rymer J, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, Velazquez E, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2018, 123: 813-819. PMID: 30598241, DOI: 10.1016/j.amjcard.2018.11.038.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLV ejection fractionAortic stenosisValve implantationEjection fractionLV massCardiac hemodynamicsBaseline LV ejection fractionLeft ventricle mass indexPost-TAVI paravalvular leakLV global longitudinal strainDuke University Medical CenterBaseline LV massLV mass regressionSevere aortic stenosisVentricle mass indexGlobal longitudinal strainTreatment of patientsUniversity Medical CenterGreat clinical successTAVI patientsReverse remodelingTransthoracic echocardiographyMedian ageSociety of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization
Bouabdallaoui N, Stevens SR, Doenst T, Petrie MC, Al-Attar N, Ali IS, Ambrosy AP, Barton AK, Cartier R, Cherniavsky A, Demondion P, Desvigne-Nickens P, Favaloro RR, Gradinac S, Heinisch P, Jain A, Jasinski M, Jouan J, Kalil RAK, Menicanti L, Michler RE, Rao V, Smith PK, Zembala M, Velazquez EJ, Al-Khalidi HR, Rouleau JL, Investigators F. Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. Circulation Heart Failure 2018, 11: e005531. PMID: 30571194, PMCID: PMC6309904, DOI: 10.1161/circheartfailure.118.005531.Peer-Reviewed Original ResearchConceptsPostoperative mortality riskCoronary artery bypassThoracic Surgeons risk scoreEuroScore 2Left ventricular dysfunctionContemporary cohortVentricular dysfunctionArtery bypassSTS scoreMortality riskRisk scoreSTICH patientsSTICH trialPostoperative mortalityUndergoing coronary artery bypassLeft ventricle ejection fractionVentricle ejection fractionGood c-statisticLow-risk scoresSurgical revascularizationSurvival benefitCardiac surgeryConsecutive patientsEjection fractionCC patientsLong-term outcomes of mitral regurgitation by type and severity
Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal 2018, 203: 39-48. PMID: 30015067, DOI: 10.1016/j.ahj.2018.05.001.Peer-Reviewed Original ResearchConceptsMR severityCause deathIschemic MRSurvival rateCause death riskCoronary artery diseaseLong-term outcomesAbsolute mortality ratesQualifying patientsArtery diseaseEchocardiography studyMitral regurgitationVentricular sizeIndeterminate causeBaseline severityDeath riskSevere MREchocardiography laboratoryHigh riskMortality rateClinical settingPatientsValve morphologySeverityMyxomatousThe relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients
Friedman DJ, Fudim M, Overton R, Shaw LK, Patel D, Pokorney SD, Velazquez EJ, Al-Khatib SM. The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. American Heart Journal 2018, 201: 17-24. PMID: 29910051, PMCID: PMC6309220, DOI: 10.1016/j.ahj.2018.03.017.Peer-Reviewed Original ResearchConceptsLeft ventricular assist devicePrimary prevention ICD patientsAppropriate ICD therapyVentricular ejection fractionImplantable cardioverter defibrillatorICD therapyICD implantationEjection fractionICD patientsMultivariable Cox proportional hazards modelsPrimary prevention implantable cardioverter defibrillatorsCo-primary study endpointsPrimary prevention ICD recipientsFollow-up left ventricular ejection fractionLeft ventricular ejection fractionCox proportional hazards modelComposite of timeLong-term followProportional hazards modelVentricular assist deviceLong-term riskBaseline LVEFLVEF improvementAdverse eventsComposite endpointDiastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study
Butler J, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, Shah SJ, Shah SH, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Braunwald E. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal Of Cardiac Failure 2018, 24: 255-265. PMID: 29482027, PMCID: PMC5880702, DOI: 10.1016/j.cardfail.2018.02.001.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsGlobal HealthHeart Failure, DiastolicHIVHIV InfectionsHumansIncidencePrognosisStroke VolumeVentricular Function, LeftConceptsDiastolic dysfunctionAntiretroviral Therapy studyAntiretroviral therapyMyocardial fibrosisHeart functionMyocardial stressHuman immunodeficiency virus (HIV) infectionAge-matched control subjectsTherapy studiesLV diastolic dysfunctionVentricular systolic dysfunctionImmunodeficiency virus infectionCardiac magnetic resonance examinationHuman immunodeficiency virusMarkers of fibrosisImmune system activationSubclinical myocardial necrosisMagnetic resonance examinationOngoing inflammationSystolic dysfunctionAtrial functionCardiac involvementSystemic inflammationHIV individualsMyocardial effectsImpaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block
Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo JA, Velazquez EJ, Daubert JP. Impaired Recovery of Left Ventricular Function in Patients With Cardiomyopathy and Left Bundle Branch Block. Journal Of The American College Of Cardiology 2018, 71: 306-317. PMID: 29348023, PMCID: PMC8352572, DOI: 10.1016/j.jacc.2017.11.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedBundle-Branch BlockCardiomyopathiesCohort StudiesElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedRecovery of FunctionTreatment OutcomeVentricular Function, LeftConceptsGuideline-directed medical therapyLeft bundle branch blockCardiac resynchronization therapyWide QRS durationBundle branch blockQRS durationLVEF improvementQRS morphologyReduced LVEFBranch blockLeft ventricular ejection fraction improvementVentricular ejection fraction improvementEjection fraction improvementMean LVEF improvementNarrow QRS durationSevere valve diseaseFirst-line therapyHeart failure hospitalizationLeft ventricular functionVentricular assist deviceBaseline electrocardiographyFailure hospitalizationCombined endpointSignificant comorbiditiesResynchronization therapy
2017
Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration
Sze E, Dunning A, Loring Z, Atwater BD, Chiswell K, Daubert JP, Kisslo JA, Mark DB, Velazquez EJ, Samad Z. Comparison of Incidence of Left Ventricular Systolic Dysfunction Among Patients With Left Bundle Branch Block Versus Those With Normal QRS Duration. The American Journal Of Cardiology 2017, 120: 1990-1997. PMID: 28958452, DOI: 10.1016/j.amjcard.2017.08.003.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic dysfunctionLeft bundle branch blockVentricular systolic dysfunctionBundle branch blockEjection fractionBaseline echocardiogramSystolic dysfunctionBranch blockQRS durationRisk factorsRelative riskLeft ventricular assist deviceNarrow QRS durationCohort of patientsNormal QRS durationFinal study cohortCommon risk factorsComparison of incidenceVentricular assist deviceHeart transplantStudy cohortLBBB patientsHigh incidencePatientsEchocardiogramMeasures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis
Lekavich CL, Barksdale DJ, Wu JR, Neelon V, Crandell J, Velazquez EJ. Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. Journal Of Cardiac Failure 2017, 23: 659-665. PMID: 28716687, PMCID: PMC5585062, DOI: 10.1016/j.cardfail.2017.07.395.Peer-Reviewed Original ResearchConceptsVentricular-arterial couplingControl groupEchocardiographic markersEjection fractionHeart failureControl subjectsCase groupHigher oddsConditional logistic regression analysisMatched Case-Control AnalysisDate of echocardiographyIncident heart failureConditional logistic regressionLogistic regression analysisCase-control analysisTimes higher oddsIncident HFpEFAtrial diameterTransthoracic echocardiogramProspective studyStudy cohortMortality implicationsUse of EESHFpEFVentricular elastanceLeft ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization
Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Failure 2017, 4: 432-439. PMID: 29154416, PMCID: PMC5695196, DOI: 10.1002/ehf2.12159.Peer-Reviewed Original ResearchConceptsAcute heart failure hospitalizationVentricular global longitudinal strainAbnormal LV-GLSLV-GLSHeart failure hospitalizationGlobal longitudinal strainAcute HFpEFFailure hospitalizationEjection fractionHeart failureLongitudinal strainCox proportional hazards modelDuke University Medical CenterComposite of mortalityMedian LV-GLSWorse LV-GLSChronic heart failureWorse clinical outcomesMyocardial systolic dysfunctionSpeckle-tracking analysisProportional hazards modelUniversity Medical CenterMultivariable adjustmentSystolic dysfunctionBaseline characteristicsImpaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristicsSudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting
Rao MP, Al-Khatib SM, Pokorney SD, She L, Romanov A, Nicolau JC, Lee KL, Carson P, Selzman CH, Stepinska J, Cleland JG, Tungsubutra W, Desvigne-Nickens PM, Sueta CA, Siepe M, Lang I, Feldman AM, Yii M, Rouleau JL, Velazquez EJ. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. Circulation 2017, 135: 1136-1144. PMID: 28154006, PMCID: PMC5516272, DOI: 10.1161/circulationaha.116.026075.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCoronary Artery BypassDeath, Sudden, CardiacFemaleFollow-Up StudiesHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainPostoperative PeriodProportional Hazards ModelsReceptors, Tumor Necrosis FactorRisk FactorsStroke VolumeVentricular Function, LeftConceptsCoronary artery bypass graft surgerySudden cardiac deathEnd-systolic volume indexB-type natriuretic peptideVentricular ejection fractionSurgical ventricular reconstructionCardiac deathEjection fractionHeart failureNatriuretic peptideVentricular reconstructionPreoperative end-systolic volume indexLow left ventricular ejection fractionIncidence of SCDPredictors of SCDArtery bypass graft surgeryCoronary Artery Bypass GraftingLeft ventricular ejection fractionVolume indexArtery Bypass GraftingBypass graft surgeryIschemic heart failureContemporary clinical trialsBlinded committeeSTICH trial